Daniele Presti retweetledi

Event-Free Survival After Stereotactic Body Radiation Therapy for Oligoprogressive Metastatic Breast Cancer
clinical-breast-cancer.com/article/S1526-…
This single-institution retrospective study evaluated progression-directed radiation therapy☢️ (PDRT) in 56 patients with oligoprogressive advanced #BreastCancer treated between 2018 and 2024. Median event-free survival was 7 months, with a median time to next treatment of 8 months.
HER2-positive🧬 and Luminal A subtypes predicted improved outcomes, while lobular histology was adverse. PDRT may delay systemic therapy changes in selected patients, warranting refined selection criteria.
@riccardo_ray
@Mg_carne
@serenadicosimo
@PrestiMD
@MariaCarmenDeS1
@OncoAlert 🚨

English






















